Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
AssigneePureTech Health LLC
InventorsEric Elenko, Philip E. Murray, III, Andrew C. Miller
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a method of treating a central nervous system disorder in a patient in need thereof. The method comprises orally administering between 75 mg and 300 mg xanomeline and between 20 mg and 200 mg trospium chloride to the patient during a 24-hour period. The central nervous system disorder is selected from schizophrenia, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Lewy Body dementia, wherein use of the trospium chloride alleviates a side effect associated with use of the xanomeline.
Claims16
A single capsule formulation for oral administration comprising xanomeline and/or a salt thereof in an amount to cause a side effect chosen from nausea, vomiting, diarrhea, sweating and excess salivation;
- and trospium chloride in an amount effective to reduce the side effect associated with the oral administration of the xanomeline and/or the salt thereof.
Dependencies are inferred from the claim text.